The CMR Green Technologies IPO GMP (Grey Market Premium) has started in the grey market,…
Goldline Pharmaceutical IPO GMP Day-1: Grey Market Premium
Goldline Pharmaceutical IPO is a Book Build Issue worth ₹11.61 crores. The public issue consists completely of a fresh issue of 0.27 crore equity shares aggregating to ₹11.61 crore.
The IPO subscription for Goldline Pharmaceutical opened on May 12, 2026 and the issue will close on May 14, 2026. The basis of allotment is expected to be finalized on May 15, 2026. The company is scheduled to list its shares on the BSE SME platform, with the tentative listing date fixed for May 19, 2026.
Goldline Pharmaceutical IPO has fixed the price band at ₹41 to ₹43 per equity share. Investors can apply with a minimum lot size of 3,000 shares. The minimum investment amount required for retail investors is ₹2,58,000 for 6,000 shares based on the upper price band. For HNI investors, the minimum application requirement is 3 lots comprising 9,000 shares, amounting to ₹3,87,000.
Cumulative Capital Pvt. Ltd. is acting as the book running lead manager for the issue, while Bigshare Services Pvt. Ltd. has been appointed as the registrar. The market maker for the IPO is Nirman Share Brokers Pvt. Ltd.
Goldline Pharmaceutical IPO GMP Live Rates day by day.
| Date | IPO GMP | GMP Trend | Gain |
|---|---|---|---|
| 17 May | ₹17 |  |
39.53% |
| 11 May | ₹16 | |
37.21% |
| 9 May | ₹8 | |
18.60% |
| 8 May | ₹7 | |
16.28% |
| 7 May | ₹- | – | -% |
RFBL Flexi Pack IPO Details
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹41 to ₹43 Per Share |
| Issue Size | Approx ₹12 Crores |
| Fresh Issue | Approx ₹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
RFBL Flexi Pack IPO Dates
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Refunds | May 18, 2026 |
| Credit to Demat Account: | May 18, 2026 |
| IPO Listing Date: | May 19, 2026 |
| IPO Bidding Cut-off Time: | May 14, 2026 – 5 PM |
Company Overview
Goldline Pharmaceutical Ltd. is a rapidly growing pharmaceutical company established on 28 February 2005 and headquartered in Nagpur, Maharashtra. Founded by Mr. Amol Mujumdar, the company has expanded its operations across 9 Indian states including Maharashtra, Chhattisgarh, Madhya Pradesh, Odisha, Tamil Nadu, Rajasthan, Jharkhand, Goa, and Bihar. The company focuses on delivering high-quality therapeutic products while continuously strengthening its market presence through innovation, customer satisfaction, and efficient marketing strategies.
Goldline Pharmaceutical operates with a dedicated marketing and product management team that regularly updates its portfolio with new formulations and advanced drug delivery systems. The company has successfully introduced products such as C-2, TROTFIT, ENTIAL, LUKIN NXT, and MYTIFY JUNIOR, which have received strong responses from medical professionals. With a strong focus on employee development, operational excellence, and sustainable growth, Goldline Pharmaceutical continues to strengthen its position in the Indian pharmaceutical industry.
Related Posts
